Description
BLOOD AND BLOOD PRODUCTS - OPTION YEAR 1 ADDITIONAL FUNDING TO MEET INCREASED FY19 DEMAND FOR BLOOD AND BLOOD PRODUCTS.
Base award description: IGF::OT::IGF BLOOD AND BLOOD PRODUCTS - OPTION 1
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2018-10-01+$223,387= $223,387
- Mod P000012019-08-09+$15,000= $238,387
- Mod P000022019-08-27+$50,000= $288,387
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2018-10-01 | +$223,387 | $223,387 | IGF::OT::IGF BLOOD AND BLOOD PRODUCTS - OPTION 1 |
| Mod P00001· FUNDING ONLY ACTION | 2019-08-09 | +$15,000 | $238,387 | BLOOD AND BLOOD PRODUCTS - OPTION 1 ADDITIONAL FUNDING TO MEET INCREASED FY19 DEMAND FOR BLOOD AND BLOOD PRODU… |
| Mod P00002· FUNDING ONLY ACTION | 2019-08-27 | +$50,000 | $288,387 | BLOOD AND BLOOD PRODUCTS - OPTION YEAR 1 ADDITIONAL FUNDING TO MEET INCREASED FY19 DEMAND FOR BLOOD AND BLOOD… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI NEVML7ZDHZC7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24926N0117 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $299,043 | FY2026 |
| 36C24925N0051 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $220,676 | FY2025 |
| 36C24924N0066 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $171,294 | FY2024 |
| 36C24923A0004 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36C24923N0116 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $214,347 | FY2023 |
| 36C24922N0027 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · Q508 · MEDICAL- HEMATOLOGY | $156,844 | FY2022 |
Other recipients under Q508 from 249-NETWORK CONTRACT OFFICE 9 (36C249) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24925P0108 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $51,105 | FY2025 |
| 36C24923N0225 | UNIVERSITY OF LOUISVILLE | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $56,742 | FY2023 |
| 36C24923N0031 | UNIVERSITY OF LOUISVILLE | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $117,554 | FY2023 |
| 36C24923N0024 | AMERICAN NATIONAL RED CROSS, THE | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $1,656,004 | FY2023 |
| 36C24922P0007 | VITALANT | 249-NETWORK CONTRACT OFFICE 9 (36C249) | $101,804 | FY2022 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C24919N0058_3600_VA24918D20344_3600 · retrieved 2026-09-26.